ACM
BCTXW

Altium Capital Management’s BriaCell Therapeutics Corp Warrant BCTXW Stock Holding History

Altium Capital Management’s Portfolio BCTXW Stock Details BCTXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-209,540
Closed -$377K – 126
2021
Q2 		$377K Sell
209,540
-290,460
-58% -$363K 0.09% 125
2021
Q1 		$535K Buy
+500,000
New +$489K 0.15% 115

Other funds holding BCTXW

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Altium Capital Management's BCTXW Position: Q3 2021 in Review

Altium Capital Management sold out of BriaCell Therapeutics Corp Warrant (BCTXW) in Q3 2021, closing a stake of 209,540 shares — an estimated $377K sold.

Altium Capital Management first reported a position in BCTXW in Q1 2021 and held it in 2 quarters. The position peaked at $535K in Q1 2021. 8 funds tracked by Wall St. Rank hold BCTXW as of Q3 2021.

  • Altium Capital Management reported no remaining BriaCell Therapeutics Corp Warrant position as of Q3 2021 after selling out during the quarter.
  • Altium Capital Management sold 209,540 BriaCell Therapeutics Corp Warrant shares in Q3 2021, an estimated $377K.
  • Altium Capital Management first reported a position in BriaCell Therapeutics Corp Warrant in Q1 2021 and held it in 2 quarters.
  • Altium Capital Management's BriaCell Therapeutics Corp Warrant position peaked at $535K in Q1 2021.
  • 8 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q3 2021.

Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.